Keyword: Yescarta (axicabtagene ciloleucel)
Eisai and Celgene veteran Michael Amoroso will take on the challenge of making Gilead's entrance into CAR-T cancer treatments a success.
Gilead and Novartis CAR-T cancer drugs Yescarta and Kymriah won an EMA committee backing for marketing approval.
Gilead's promotion of Andrew Dickinson, and a fresh licensing deal, could signal that Gilead's looking outside its own walls for growth opportunities.
Gilead will locate the European manufacturing site for its CAR-T therapy Yescarta at a Netherlands airport to ensure quick turnaround for its patients.
Gilead may have some exciting prospects ahead, but for now, its cash-cow hepatitis C business is a big drag. The good news? It's a 'trough year.'
If the competition between Novartis and Gilead in relapsed large B-cell lymphoma comes down to price, it will be a close race.
CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's requested add-on payment.
A host of challenges that drove Gilead's revenues down 14% last year didn’t stop its board from boosting the CEO’s pay package to $15.4 million.
Never underestimate the power of positivity, which triumphed in the latest round of voting in FiercePharma’s drug-naming shootout.